ADAGIO MEDICAL HOLDINGS INC (ADGM) Stock Price, Forecast & Analysis
USA - NASDAQ:ADGM - US00534B1008 - Common Stock
ADGM Key Statistics, Chart & Performance
The current stock price of ADGM is 0.8354 USD. In the past month the price decreased by -40.8%. In the past year, price decreased by -65.73%.
ADGM Latest News, Press Relases and Analysis
ADGM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.1 | 217.97B | ||
| ISRG | INTUITIVE SURGICAL INC | 65.55 | 202.33B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.87 | 143.70B | ||
| SYK | STRYKER CORP | 27.54 | 138.68B | ||
| BDX | BECTON DICKINSON AND CO | 13.34 | 55.12B | ||
| IDXX | IDEXX LABORATORIES INC | 54.72 | 55.20B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.21 | 50.10B | ||
| RMD | RESMED INC | 24.73 | 35.72B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.56 | 32.61B | ||
| DXCM | DEXCOM INC | 32.08 | 23.40B | ||
| PODD | INSULET CORP | 74.63 | 24.01B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.05 | 17.72B |
Related stock screener links
About ADGM
Company Profile
Adagio Medical Holdings, Inc. is a medical device company, which engages in the development ablation technologies for the treatment of cardiac arrhythmias. The company is headquartered in Laguna Hills, California and currently employs 86 full-time employees. The company went IPO on 2021-02-26. The company is focused on developing proprietary Ultra-Low Temperature Cryoablation technology that creates contiguous, transmural lesions to treat cardiac arrhythmias, with an emphasis on ventricular tachycardia. The company is developing and placing on the European Union (EU) market ablation technologies for the treatment of cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. Its product portfolio consists of three product families: iCLAS atrial ULTC catheter and accessories, vCLAS ventricular ULTC catheter, and Cryopulse atrial PFCA catheter and accessories. All of these catheters share the same ULTC cryoablation console. The iCLAS system is CE-marked with the indication for treatment of paroxysmal atrial fibrillation, persistent atrial fibrillation and atrial flutter. The vCLAS ventricular catheter has been specifically designed for the treatment of ventricular arrhythmia.
Company Info
ADAGIO MEDICAL HOLDINGS INC
26051 Merit Circle, Suite 102
Laguna Hills CALIFORNIA US
Employees: 86
Phone: 19493481188
ADAGIO MEDICAL HOLDINGS INC / ADGM FAQ
What does ADAGIO MEDICAL HOLDINGS INC do?
Adagio Medical Holdings, Inc. is a medical device company, which engages in the development ablation technologies for the treatment of cardiac arrhythmias. The company is headquartered in Laguna Hills, California and currently employs 86 full-time employees. The company went IPO on 2021-02-26. The company is focused on developing proprietary Ultra-Low Temperature Cryoablation technology that creates contiguous, transmural lesions to treat cardiac arrhythmias, with an emphasis on ventricular tachycardia. The company is developing and placing on the European Union (EU) market ablation technologies for the treatment of cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. Its product portfolio consists of three product families: iCLAS atrial ULTC catheter and accessories, vCLAS ventricular ULTC catheter, and Cryopulse atrial PFCA catheter and accessories. All of these catheters share the same ULTC cryoablation console. The iCLAS system is CE-marked with the indication for treatment of paroxysmal atrial fibrillation, persistent atrial fibrillation and atrial flutter. The vCLAS ventricular catheter has been specifically designed for the treatment of ventricular arrhythmia.
What is the stock price of ADAGIO MEDICAL HOLDINGS INC today?
The current stock price of ADGM is 0.8354 USD. The price decreased by -1.31% in the last trading session.
Does ADGM stock pay dividends?
ADGM does not pay a dividend.
How is the ChartMill rating for ADAGIO MEDICAL HOLDINGS INC?
ADGM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
ADGM Technical Analysis
ADGM Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ADGM. ADGM has a bad profitability rating. Also its financial health evaluation is rather negative.
ADGM Financial Highlights
Over the last trailing twelve months ADGM reported a non-GAAP Earnings per Share(EPS) of -4.42. The EPS decreased by -273.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -205.32% | ||
| ROE | -849.98% | ||
| Debt/Equity | 1.96 |